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ABSTRACT
Loss of the gene von Hippel–Lindau (VHL) is associated with loss
of primary cilia and is causally linked to elevated levels of Aurora
kinase A (AURKA). We developed an image-based high-throughput
screening (HTS) assay using a dual-labeling image analysis strategy
that identifies both the cilium and the basal body. By using this
strategy, we screened small-molecule compounds for the targeted
rescue of cilia defects associated with VHL deficiency with high
accuracy and reproducibility. Bexarotene was identified and validated
as a positive regulator of the primary cilium. Importantly, the inability
of an alternative retinoid X receptor (RXR) agonist to rescue
ciliogenesis, in contrast to bexarotene, suggested that multiple
bexarotene-driven mechanisms were responsible for the rescue.
We found that bexarotene decreased AURKA expression in
VHL-deficient cells, thereby restoring the ability of these cells to
ciliate in the absence of VHL. Finally, bexarotene treatment reduced
the propensity of subcutaneous lesions to develop into tumors in a
mouse xenograft model of renal cell carcinoma (RCC), with a
concomitant decrease in activated AURKA, highlighting the potential
of bexarotene treatment as an intervention strategy in the clinic to
manage renal cystogenesis associated with VHL deficiency and
elevated AURKA expression.
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INTRODUCTION
Loss or mutations in the von Hippel–Lindau (VHL) gene are most
commonly associated with VHL disease and clear cell renal cell
carcinoma (ccRCC) (Kaelin, 2007). Recent advances in
understanding the role of VHL in multiple molecular pathways,
have resulted in the development of targeted therapies including
tyrosine kinase inhibitors (TKIs), monoclonal antibodies,
mammalian target of rapamycin (mTOR) inhibitors, and immune
checkpoint therapy for the treatment of ccRCC (Hsieh et al., 2017).
Although successful, these strategies have plateaued since their
inception in large part due to the development of resistance.
The molecular mechanisms underlying RCC pathogenesis are
only beginning to emerge with the identification of novel targets of
VHL (Anderson et al., 2011; Hasanov et al., 2017; Ivan et al., 2001;
Kuznetsova et al., 2003; Lai et al., 2011b; Mikhaylova et al.,
2008; Na et al., 2003; Okuda et al., 2001; Xie et al., 2009; Xue et al.,
2012) linking it to a range of cellular functions including
maintenance of mitotic spindle orientation (Hell et al., 2014;
Thoma et al., 2009) and the primary cilium (Dere et al., 2015;
Lolkema et al., 2008; Thoma et al., 2007).
VHL disease is part of a diverse group of human disorders
referred to as ‘ciliopathies’, characterized by the structural loss or
functional abnormality of the primary cilium, which is directly
linked to the cystic kidney phenotype commonly associated with
these diseases (Seeger-Nukpezah et al., 2013). The primary cilium
is a microtubule-based structure that grows and resorbs in response
to cues arising during the cell cycle and from environmental factors
(Reiter and Leroux, 2017). Several critical regulators of cilium
disassembly have been identified (Inaba et al., 2016; Inoko et al.,
2012; Kim et al., 2015b; Kinzel et al., 2010; Wang et al., 2014) with
Aurora kinase A (AURKA) being a key player involved in
resorption of the cilium (Plotnikova et al., 2012; Pugacheva et al.,
2007). We recently identified AURKA as a direct target of the E3
ligase activity of VHL (Hasanov et al., 2017), and linked elevated
AURKA to the loss of primary cilia associated with VHL deficiency
(Dere et al., 2015; Hasanov et al., 2017).
Retinoids are biologically active compounds of natural (derived
from vitamin A) and synthetic origin that are intimately involved in a
number of developmental and physiological processes (Bastien and
Rochette-Egly, 2004; Kastner et al., 1995; Uray et al., 2016). These
lipid-soluble compounds bind, as ligands, to a specific subset of
nuclear receptors called retinoic acid receptors (RARs) or retinoid X
receptors (RXRs) to directly regulate expression of genes involved in
a diverse array of cellular functions (Allenby et al., 1993; Germain
et al., 2006; Heyman et al., 1992; Levin et al., 1992). In the classical
sense, receptor-mediated retinoid signaling is a function of active
metabolites, their receptors and dimerization partners (Uray et al.,
2016). However, studies have also demonstrated the ability of
retinoids to activate several kinase cascades, suggesting that retinols
could exert their non-genomic effects via extra-nuclear interactions
(Aggarwal et al., 2006; Alsayed et al., 2001; Berry et al., 2012; Dey
et al., 2007; Lösel and Wehling, 2003; Masiá et al., 2007; Piskunov
and Rochette-Egly, 2012).
Retinoids, owing to their ability to promote cell differentiation and
cell death, have been used in clinical settings for cancers including
leukemia, cutaneous T-cell lymphomas, neuroblastomas, breast and
lung cancers, as well as for neurological diseases and, most
successfully, in treatment for dermatological disorders (Uray et al.,
2016). The efficacy of retinoids in metastatic RCC was evaluated in
the early 1990s with combination therapy reported to be moreReceived 1 May 2018; Accepted 17 October 2018
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promising than mono-therapy for treatment of RCC (Aass et al.,
2005; Berg et al., 1999; Boorjian et al., 2007; Motzer et al., 1999,
2000). Detailed evaluations revealed that all types of RAR (α, β and
γ) and RXR (α and β) subtypes of receptors are expressed in RCC,
although RXRγwas lost in advanced stage RCC (Lenko et al., 2013).
We have developed a primary image-based high-throughput
screening (HTS) assay to identify small molecules that restore cilia
in VHL-deficient cells. A customized image analysis algorithm was
established using a dual-labeling strategy for the cilium and basal
body that significantly increased accuracy and reproducibility.
Bexarotene, a synthetic rexinoid was identified and validated as a
bona fide regulator of primary cilia in hTERT RPE1 and mouse
embryonic fibroblast (MEF) cells with an acute loss of VHL. In
contrast to bexarotene, LG100268 (LG268), an alternative RXR
agonist, failed to rescue defective cilia in VHL-deficient cells
whereas TTNPB, an RAR agonist, only partially rescued cilia,
suggesting that the rescue of cilia in VHL-deficient cells might be
specific to bexarotene. Importantly, bexarotene-driven restoration of
primary cilia in VHL-deficient cells correlated to a decrease in
AURKA expression. Treatment of an RCC 786-0 tumor xenograft
model with bexarotene showed a dramatic decrease in tumor
incidence in mice treated with bexarotene compared to the vehicle-
treated group, which was reflected in a tumor volume that was
significantly lower in bexarotene-treated animals compared to that
in vehicle controls. These data correlated to a corresponding
decrease in AURKA activity in tumors from bexarotene-treated
animals that did progress to fulminant tumors, indicative of the
efficacy of bexarotene in modulating AURKA in vivo. These data
establish bexarotene as a regulator of primary cilia and highlight its
potential use as a clinical intervention strategy in VHL disease and
other ciliopathies where AURKA expression is elevated.
RESULTS
Development of a primary HTS assay identifies small
molecules that rescue primary cilia in VHL-deficient cells
Loss of VHL results in loss of primary cilia arising in part due to
elevated AURKA levels (Dere et al., 2015; Hasanov et al., 2017).
We developed a HTS assay to identify small molecules that could
restore primary cilia in VHL-deficient cells, with the dual goal of
identifying novel therapeutic targets and signaling pathways
involved in aberrant ciliogenesis associated with loss of VHL.
We used an in vitro ciliogenesis model, which we have previously
established (Dere et al., 2015; Hasanov et al., 2017), wherein
immortalized human retinal pigmented epithelial (hTERT-RPE1)
cells transfected with VHL siRNA (siVHL, to induce an acute loss
of VHL) were stimulated to ciliate by serumwithdrawal for 48 h.We
showed that this acute loss of VHL (siVHL) resulted in a significant
decrease in the ability of hTERT RPE1 cells to ciliate compared to
control siRNA (siC)-transfected cells (Dere et al., 2015; Hasanov
et al., 2017). For the primary screen, the assay was re-developed to
be amenable to a 384-well plate format and was performed as
detailed in the schematic shown in Fig. 1A. hTERT-RPE1 cells
were transfected with siC or siVHL, 24 h after seeding (7000 cells/
well), and were induced to ciliate by the simultaneous withdrawal of
serum and treatment with either vehicle (DMSO) or compound
(detailed in Table S1) at a dose of 10 µM for 48 h. The efficiency
of VHL knockdown was assessed via RT-PCR, which showed a
70–80% decrease in VHL transcript levels (shown in Fig. 4D)
corroborating our previously established data (Dere et al., 2015;
Hasanov et al., 2017). At the end of the incubation period (48 h),
cells were immunostained for acetylated α-tubulin (a cilia marker)
and pericentrin (a basal body marker) and imaged at 20×
magnification (4 fields/well) using an InCell6000 confocal
imaging platform.
Next, we developed a customized image analysis algorithm to
score and compute the number of ciliated cells present after
treatment of the VHL-deficient cells with vehicle or compound. We
used a strategy of dual labeling of the primary cilium and the basal
body, which yielded high accuracy and reproducibility as it
precluded the inclusion of non-ciliary cytoplasmic acetylated
α-tubulin signal (false positives for primary cilia). Using a
K-mean segmentation model, a surface mask was created, for
each of the cilium, basal body and nucleus (Fig. 1B). The algorithm
was designed so that only signal obtained from an intersecting mask
for the cilium and basal body was taken as a true signal (Fig. 1C).
Since ‘hits’ identified from an HTS assay are obtained from a single
well, and need to be sufficiently robust and reliable to ensure
confidence in the data, we used the statistical measure of Z′, which
accounts for dynamic range and signal variability. Our HTS assay
yielded a Z′ value of 0.62, which is above the accepted value of 0.4
(Z′ approaching 1 is considered most desirable), and demonstrated
the tractability of our image-based HTS assay. To eliminate wells in
which a false signal might be generated from only a few cells that
survived treatment (i.e. treatment resulted in significant toxicity),
a toxicity filter (with a stringent 80% survival rate as compared to
the scrambled siRNA-transfected cells) was further applied to
post-acquisition image analysis, which gave us the raw mean
percentage of ciliated cells (Fig. 1D). Finally, computation of
Z-scores identified compounds, that is positive ‘hits’, at three
standard deviations above the population mean (Fig. 1E). Two
compounds, bexarotene (a synthetic rexinoid) and BEZ235 (a dual
PI3K and mTOR inhibitor) were identified as potential ‘hits’ and
modulators of primary cilia in VHL-deficient cells (Fig. 1E).
Bexarotene is a bona fide positive regulator of primary cilia
Given that bexarotene (LGD1069) (Fig. 2A), yielded a mean
Z-score of 4.8, we moved bexarotene into secondary validation
assays to confirm its role as a positive regulator of the primary
cilium. To validate bexarotene as a bona fide hit, dose–response
studies were performed with freshly procured compound (two
independent sources, distinct from that used for the primary assay)
to assess the ability of bexarotene to rescue cilia. Dose–response
curves were generated using hTERTRPE1 cells transfected with siC
or siVHL, and treated with three low doses of compound (0.1 µM,
0.3 µM and 1 µM) to prevent off-target effects that might occur at
the higher dose (10 µM) used for the primary screen. Image analysis
using our customized algorithm established bexarotene (Fig. 2B,C)
as a bona fide ‘hit’ that successfully rescued aberrant ciliogenesis in
cells with VHL knockdown. We observed between a 33% to 40%
increase in the number of cells that recovered their ability to
ciliate in the absence of VHL (cells with a 70% knockdown of
VHL) when treated with bexarotene (0.1–1.0 µM, respectively)
compared to the vehicle (DMSO)-treated controls (Fig. 2B). To
further validate these data, we generated VhlloxP/loxP MEFs stably
expressing a tamoxifen-inducible ERCre recombinase, which, when
treated with 4-hydroxy tamoxifen, resulted in a 90% knockdown of
Vhl mRNA expression (Fig. 2D). Next, to determine the effect of
Vhl loss on primary cilia, the MEFs were maintained in serum-free
medium with concurrent treatment with tamoxifen for 48 h to
induce ciliation. As anticipated, we saw a statistically significant
decrease in the percentage of ciliated cells under conditions of
tamoxifen treatment compared to untreated cells (Fig. 2E,F). The
decrease in ciliation frequency was also accompanied by the
presence of shorter cilia, which is comparable to our observations in
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hTERT RPE1 cells with VHL knockdown (Fig. 2E). Importantly,
simultaneous treatment of MEFs with tamoxifen and bexarotene
(1.0 µM) in conditions of serum starvation (to induce ciliation)
almost completely rescued the ability of cells to ciliate (Fig. 2E,F),
further validating our data from the primary screen.
Alternative RXR and RAR agonists fail to rescue ciliogenesis
in VHL-deficient cells
Given that bexarotene binds to and activates RXRs, we evaluated
the ability of LG100268 (LG268) (Fig. 3A), an alternative rexinoid
with a 10-fold-higher affinity for RXR compared to bexarotene (Liu
et al., 2002), to modulate primary cilia in VHL-deficient cells.
Surprisingly, in contrast to treatment with bexarotene, which
increased the number of cells that could ciliate in the absence of
VHL (Fig. 2B,F), treatment of cells with LG268 failed to rescue the
ciliation defects in VHL-deficient cells (Fig. 3B,E). Next, to
evaluate whether the effects of bexarotene could be mimicked by
ligand-mediated activation of retinoic acid receptors (RARs) we
used an analog of retinoic acid, TTNPB (Fig. 3C), to assess ciliation
in VHL-deficient cells. In contrast to LG268, treatment of VHL-
deficient cells with TTNPB only partially rescued the ability of
these cells to ciliate (P=0.05) at the 1.0 µM dose (Fig. 3D,E)
suggesting that the effects of bexarotene on primary cilia could in
part be receptor mediated.
Bexarotene rescues cilia by regulating AURKA expression
We and others have found elevated AURKA levels to be causally
linked to loss of primary cilia (Dere et al., 2015; Hasanov et al.,
2017; Lolkema et al., 2008; Thoma et al., 2007) in the setting of
VHL deficiency. This is believed to arise in part from elevated levels
of AURKA, which interacts with its partner NEDD9 to activate
HDAC6 and results in the destabilization of the ciliary axoneme
(Pugacheva et al., 2007). To determine whether bexarotene rescued
ciliogenesis by modulating AURKA expression, we initially probed
Fig. 1. Primary image-based HTS assay. (A) Schematic depicting the workflow used for the development of the primary screen. (B) Representative images
depicting the surface mask generated for the primary cilium (green) and the basal body (red) for further image analysis. (C) Logic used to develop the dual
labeling of cilia and basal bodies for image analysis. (D) Graphical representation of data obtained following image analysis showing percentage of ciliated
cells for each of the treated compounds as indicated. siVHL DMSO (vehicle), red bar; and siC (scrambled control) DMSO (vehicle); green bar. (E) Graphical
representation of the Z-normalized percentage of ciliated cells for each of the indicated treatments. The positive hits are magnified and shown in the inset to
the left. Scrambled control (siC) DMSO (vehicle), green bar.
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Fig. 2. See next page for legend.
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AURKA levels in cellular lysates from VHL-deficient cells treated
with bexarotene for 48 h (to induce cilia formation). We found that
bexarotene decreased AURKA protein levels in a dose-dependent
manner (Fig. 4A), with a parallel decrease in NEDD9 expression
(AURKA binds to and stabilizes NEDD9; Pugacheva et al., 2007)
(Fig. 4A). Quantification revealed a 50% reduction in AURKA
levels in bexarotene-treated cells with an acute loss of VHL
(siVHL), which decreased to match AURKA levels in bexarotene-
treated control transfected (siC) cells (Fig. 4B). Given that
bexarotene, in its canonical role is an RXR agonist, is known to
modulate gene expression at the level of transcription (Uray et al.,
2016), we next assessed AURKA mRNA levels in cells treated with
bexarotene. Analogous to the reduction in AURKA protein
expression at the 1.0 µM dose, we found a significant decrease
(40%) in AURKA transcript levels (Fig. 4C). Importantly,
bexarotene treatment also led to a dose-dependent increase in
VHL mRNA expression in control (siC) transfected cells (Fig. 4D).
However, this increase in VHL mRNA was suppressed in cells
where VHL was knocked down by siRNA (Fig. 4D).
VHL-deficient RCC cell lines (786-0) lack primary cilia (Dere
et al., 2015; Hasanov et al., 2017; Lolkema et al., 2008; Thoma et al.,
2007); however, re-expressing VHL in these cell lines (786-0 VHLL)
does not elicit cilia formation under the conditions used in our
studies (Fig. 4E,F). Furthermore, treatment of the VHL-null 786-0
cells with bexarotene also failed to drive these RCC cells to ciliate
(Fig. 4G). Although we do observe a decrease in AURKA levels
following re-expression of VHLL, the inability of bexarotene to elicit
a similar decrease in AURKA levels lead us to determine whether
AURKA activity was modulated by bexarotene. As shown in Fig. 4I,
the levels of phosphorylated AURKA decreased in 786-0 cells
treated with bexarotene suggesting that bexarotene treatment might
reduce AURKA levels or could effectively reduce AURKA activity.
Bexarotene decreases tumor incidence in a mouse
xenograft model of RCC
Given that RCC cells rarely ciliate in culture, it would be extremely
challenging to evaluate rescue of cilia in a an animal model with
monogenic loss of Vhl (which also fails to display a renal phenotype;
Hsu, 2012) or a xenograft model. However, to determine whether
bexarotene could affect tumor growth in VHL-deficient cells by
modulating AURKA, we established an RCC tumor xenograft using
786-0 (VHL-deficient) cells in athymic nude mice (Foxn1nu). As
outlined in the schematic shown in Fig. 5A, bexarotene treatment was
started 2 weeks after the cells were injected in nude mice. We found
that 50 mg/kg body weight/day bexarotene treatment drastically
reduced tumor take to 50% of that seen in vehicle-treated mice
(Table 1). Mice in the vehicle group showed a steady increase in
tumor incidence, resulting in 100% of lesions/nodules reaching a size
greater than 200 mm3 (tumor positive) (Fig. 5B; Table 1) whereas
bexarotene treatment led to only 55% of the nodules reaching a size
greater than 200 mm3. Although tumor take rates differed
significantly, once the tumors presented, the growth rates of the
tumors were identical in bexarotene- and vehicle-treated mice.
Corroborating these data, immunohistochemistry analysis of tumor
tissue using H&E and Ki67 staining failed to reveal any differences
between vehicle- and bexarotene-treated animals (Fig. 5C,D). Tumor
volumes (Fig. 5E) and tumor weights (Fig. 5F) measured post
euthanasia (10 weeks after commencement of bexarotene treatment)
were concomitantly reduced in bexarotene-treated animals compared
to the vehicle controls. Although the 786-0 xenograft tumors would
not form cilia, we evaluated the efficacy of bexarotene in modulating
AURKA. Phosphorylation of AURKA (at T288) was evaluated in
tumors from xenografts that did indeed progress to fulminant tumors
(>200 mm3, tumor positive) in bexarotene- and vehicle-treated
animals (Fig. 5G). Quantification revealed that bexarotene retained
its ability to modulate AURKA activity, which was significantly
reduced in bexarotene-treated xenografts compared to that seen in
vehicle controls (Fig. 5H). These data suggest that bexarotene might
be relevant in preventing tumor onset and reducing tumor growth.
DISCUSSION
We have developed an image-based HTS assay, using a dual-
labeling strategy for analysis, that reliably identifies both the cilium
and the basal body, enabling screening of small-molecule
compounds for the targeted rescue of cilia defects associated with
VHL deficiency. A pilot screen with 146 compounds identified
bexarotene as a bona fide regulator of the primary cilium.
Bexarotene decreased AURKA expression and activity, providing
a potential mechanism by which ciliogenesis was restored in the
setting of VHL loss. Importantly, the inability of alternative RXR or
RAR agonists to fully rescue ciliogenesis, in contrast to bexarotene,
suggests that the impact on ciliogenesis might be bexarotene
specific. Finally, treating RCC (786-0) tumor xenografts with
bexarotene prior to tumor formation dramatically reduced tumor
take (incidence) in mice compared to vehicle-treated controls.
Although half the nodules in bexarotene-treated animals did not
progress to fulminant tumors, the efficacy of bexarotene in
modulating AURKA remained unaltered in tumors from these
xenografts, highlighting the potential of exploring bexarotene as an
intervention strategy in the clinic to manage renal cystogenesis
associated with VHL disease and RCC.
The importance of the primary cilium is well established,
although the dynamics that govern cilia formation and disassembly
are only just beginning to emerge. The recent advent of large
proteomic studies and bioinformatics identified thousands of
proteins associated with the cilium and/or basal body referred to
as the ‘ciliome’ (Gherman et al., 2006; Inglis et al., 2006). Although
proteomic approaches are powerful, the lack of functional links
between these candidate proteins and cilia dynamics has led to the
development of targeted screens using reverse genetic approaches to
Fig. 2. Bexarotene dose–response curves validate its ability to restore
cilia in VHL-deficient cells. (A) Chemical structure of bexarotene.
(B) Graphical representation of the percentage of ciliated cells normalized to
the result for vehicle (set at 100%), in response to differing doses of bexarotene
(Bex) in VHL-proficient (siC) and VHL-deficient (siVHL) cells. #P<0.001
compared to siC vehicle (DMSO)-treated control; *P<0.05 denotes
statistical significance compared to siVHL vehicle (DMSO)-treated control.
(C) Representative images taken with a 60× objective showing primary cilia
(green) and basal bodies (red). Nuclei are counterstained with DAPI in blue.
Insets show a magnified image of a cilium for each of the indicated conditions.
Scale bars: 5 µm (siC); 10 µm (siVHL). (D) Graph indicating the fold change in
Vhl mRNA transcript in VhlloxP/loxP MEF cells stably expressing a tamoxifen-
inducible ERCre recombinase. Black bars denote VhlloxP/loxP MEF controls,
and gray bars indicate the VhlloxP/loxP MEFs treated with tamoxifen to induce
the Cre recombinase. (E) Representative images (taken with a 60× objective)
from VhlloxP/loxP MEFs controls (upper left), VhlloxP/loxP MEFs treated with
tamoxifen (upper right) and VhlloxP/loxP MEFs treated with tamoxifen and
bexarotene for 48 h (bottom center). Cells were labeled for acetylated α-tubulin
(cilia marker in green) and counterstained with DAPI in blue. Insets show a
magnified image of a cilium for each of the indicated conditions. Scale bars:
5 µm. (F) Graphical representation of the percentage of ciliated cells,
normalized to the result for control (set at 100%; −Tam, black bar), for
tamoxifen-treated (+Tam, gray bar) and tamoxifen- and bexarotene-treated
(+Tam +Bex, gray bar) VhlloxP/loxP MEFs. Results are for n=2 with >450 cells
counted per condition. * denotes statistical significance between the groups
as indicated.
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Fig. 3. See next page for legend.
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specifically identify genes that modulate ciliogenesis. In addition to
these global siRNA strategies (Wheway et al., 2015), key regulators
of the cilium have been further identified using both screens aimed
at targeting smaller subsets of therapeutically relevant genes across
the genome (Kim et al., 2010; Lai et al., 2011a) and more specific
screens like those evaluating the contributions of ion channels on
ciliogenesis (Slaats et al., 2015). The strategy employed in our study
differs from previous screens in its use of an unbiased approach,
agnostic to the genes involved in ciliogenesis, to identify small-
molecule compounds that can restore cilia in VHL-deficient cells.
Use of a dual labeling scheme and increased throughput enabled the
acquisition of images at 20× magnification, which further increased
accuracy of image analysis and minimized false positives arising
from the inclusion of cytoplasmic acetylated α-tubulin.
We identified bexarotene as a regulator of ciliogenesis in VHL-
deficient cells. Bexarotene is a U.S. Food and Drug Administration
(FDA) approved synthetic rexinoid with known function in
activating RXRs (Henney, 2000). Ligand binding and activation
of the cognate RXR receptors, modulates gene expression arising
from the homo- or hetero-dimerization of these receptors (with
RAR, PPAR, VDR and others) (Uray et al., 2016). Our observation
that bexarotene modulated ciliogenesis, in contrast to an alternate
RXR agonist (LG268, which has a 10-fold higher affinity for RXR
compared to bexarotene; Liu et al., 2002) that failed to rescue
ciliogenesis, suggests that bexarotene might act by a mechanism
other than targeting RXRs, although the two may not necessarily be
mutually exclusive. Recently, Src was identified as a novel ‘off-
target protein’ modulated by bexarotene; in silico modeling studies
suggested that bexarotene could inhibit Src by binding its ATP-
binding pocket (Kim et al., 2015a). In addition, bexarotene has also
been reported to activate p53 by post-translational modifications,
namely phosphorylation on serine 15, which regulated p53
downstream targets such as p21, and could also modulate
AURKA both at the transcript and protein level (Nieto-
Rementería et al., 2009). Our data demonstrate the ability of
bexarotene to modulate AURKA mRNA expression only at the
1.0 µM dose but not at the lower doses that impact AURKA protein
levels. It will now be interesting to determine whether our data
identifying bexarotene as a modulator of AURKA expression in
VHL-deficient cells provides yet another ‘off-target protein’ that
might be modulated by bexarotene in an RXR-independent manner.
AURKA, in a non-mitotic role was identified as a regulator of
cilium disassembly. Elevated AURKA activity resulted in activation
of HDAC6, a downstream target, leading to the destabilization of the
microtubule-based axoneme and cilia resorption (Pugacheva et al.,
2007). We and others have shown AURKA is elevated in VHL-
deficient RCC (Dere et al., 2015; Hasanov et al., 2017; Lolkema
et al., 2008; Thoma et al., 2007), and our recent finding identified
AURKA as a target of E3 ligase activity of VHL (Hasanov et al.,
2017), providing a direct link between elevated AURKA and VHL-
null RCC. Importantly, although bexarotene modulated AURKA
transcript levels specifically at the 1.0 µM dose, it significantly
increased VHL mRNA expression at all doses. Although, rexinoids
have not been explored in the context of RCC, a previous study
reported that a combination of 13-cis retinoic acid and an HDAC
inhibitor augmented VHL expression in cells (Tavares et al., 2008).
This is especially important given the recent efforts in the field to
re-functionalize VHL using proteasome inhibition, which proved
effective in increasing mutant VHL levels (Ding et al., 2014). Mutant
VHL is degraded prematurely due to misfolding and an imbalance of
chaperonin, although it still retains its E3 ligase function (Lee et al.,
2009; Rechsteiner et al., 2011). Increasing VHL expression using
bexarotene could be an exciting and novel approach in the clinic,
especially if combined with the modulation of proteostasis.
Retinoids promote differentiation and apoptosis in cells, and this
attribute has led to their successful therapeutic application in several
cancers including acute promyelocytic leukemia (APL), Kaposi’s
sarcoma, squamous cell skin cancer, cutaneous T-cell lymphoma,
neuroblastoma, lung cancer and breast cancer (Uray et al., 2016). In
contrast to retinoids, treatment with rexinoids shows reduced
teratogenicity and toxicity with manageable side-effects, such as
hyperlipidemia (Assaf et al., 2006). The effects of retinoids in RCC
treatment were deemed more efficacious when used as part of a
combination approach compared to the anti-tumor activity of single
agents (Aass et al., 2005; Boorjian et al., 2007; Motzer et al., 1999,
2000). These data showing limited efficacyof retinoids inRCC, led to
recent efforts refocusing on identifying receptor subtypes associated
with RCC and their prognostic significance (Buentig et al., 2004;
Goelden et al., 2005; Obara et al., 2007). Our findings show the
ability of a rexinoid, bexarotene, to reduce tumor take and decrease
tumor growth in a tumor xenograft model of RCC. These data are
promising as they lay the foundation for unexplored intervention
strategies, focused on prevention, in high-risk VHL patients with
elevated AURKA expression. Bexarotene as a prevention strategy
(either singly or in combination) has found efficacy in cancers such as
lung cancer (Wang et al., 2006) and oral cavity carcinogenesis (Tang
et al., 2014). In the case of VHL disease and RCC, it would be
valuable to assess the synergistic effects of bexarotene with anti-
angiogenic drugs, and with AURKA inhibitors that can rescue the
ciliation defects associated with VHL deficiency (Dere et al., 2015;
Hasanov et al., 2017). The identification of bexarotene as amodulator
of the cilium now opens new avenues to investigate the merit of
rexinoids as a treatment strategy for ciliopathies.
MATERIALS AND METHODS
Cell culture and drug treatments
Immortalized retinal pigmented epithelial (hTERT RPE1) cells (a gift from
Gregory Pazour, University of Massachusetts Medical School, Worcester,
MA) were maintained in Dulbecco’s modified Eagle’s medium/F-12 (Life
Technologies, Carlsbad, CA). The human 786-0 VHL-deficient RCC cell
line was maintained in RPMI-1640 medium (Life Technologies). Cells were
maintained in media supplemented with 10% fetal bovine serum
(Sigma-Aldrich, St Louis, MO). All human cell lines were short tandem
repeats fingerprinted and validated using the Characterized Cell Line Core
Facility (U.T. M.D. Anderson Cancer Center). In addition, all cells used in
these studies were routinely tested and confirmed negative for mycoplasma.
Generation of VhlloxP/loxPmouse embryonic fibroblasts
VhlloxP/loxP MEFs were generated from 13.5 days post-coitum (d.p.c.)
embryos of VhlloxP/loxP mice (JAX Labs). These MEF cells were
immortalized by serial passaging in high glucose DMEM (Life
Fig. 3. Alternative RXR and RAR agonists fail to rescue ciliogenesis in
VHL-deficient cells. (A) Chemical structure of LG100268 (LG268), an RXR
agonist. (B) Graphical representation of the percentage of ciliated cells
normalized to the result for vehicle (set at 100%), in response to differing doses
of LG268 in VHL-proficient (siC) and VHL-deficient (siVHL) cells. #P<0.001
compared to siC vehicle (DMSO)-treated control. (C) Chemical structure of
TTNPB, an RAR agonist. (D) Graphical representation of the percentage of
ciliated cells normalized to the result for vehicle (set at 100%), in response to
differing doses of TTNPB in VHL-proficient (siC) and VHL-deficient (siVHL)
cells. #P<0.05 compared to siC vehicle (DMSO)-treated control; *P<0.05
compared to siVHL vehicle (DMSO)-treated control. (E) Representative
images taken with a 60× objective showing primary cilia (green) and
basal bodies (red). Nuclei are counterstained with DAPI in blue. Insets
show a magnified image of a cilium for each of the indicated conditions.
Scale bars: 5 µm.
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Fig. 4. See next page for legend.
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Technologies) supplemented with 10% FBS (Sigma-Aldrich) and penicillin-
streptomycin (Life Technologies). Immortalized MEF cells were transfected
with a tamoxifen-inducible ER-Cre vector expressing Cre recombinase fused
with a mutated ligand-binding domain for the human estrogen receptor
(ER-Cre). Stable MEF cell lines expressing ER-Cre were generated by
culturing in selection media containing 5 μg/ml blasticidin (Thermo Fisher
Scientific, Waltham, MA). Vhlflox/flox MEFs were treated with 3 μM
4-hydroxytamoxifen (Sigma-Aldrich) for 2 days for efficient Vhl knockout.
Compounds used for the primary screen (Table S1) were solubilized in
DMSO and used at a final concentration of 10 µM. Bexarotene, was
obtained from Sigma-Aldrich and Selleck Chem (Houston, TX); LG100268
and TTNPB were obtained from Sigma-Aldrich and used in the secondary
validation studies in vitro at final concentrations of 0.1 µM, 0.3 µM and
1.0 µM doses (solubilized in DMSO) for 48 h as indicated for each
individual treatment.
Primary screen and image analysis
hTERT RPE1 cells (7000 cells) were plated in each well of 384 well plates
and transfected with siC (catalog no. 001810-10-20, Dharmacon, Lafayette,
CO) or siVHL (catalog no. L-003936-00-0005, Dharmacon). Next, cells were
simultaneously treated with the compound library (Custom Clinical library
with 146 compounds, Table S1) and serum starved for 48 h to induce primary
cilia. Cells were subsequently fixed and stained for primary cilia, basal body
and nuclei (as described below). Images were obtained at 20× magnification,
four fields per well and 13 z-sections (0.5 µM steps) using an InCell6000
confocal microscope (GE Healthcare Life Sciences, Pittsburgh, PA).
Images were analyzed using Pipeline Pilot (BIOVIA, San Diego, CA)
using an algorithm customized to measure primary cilia. First, images were
subjected to a background subtraction using either Rolling Ball (set the ball
radius) or Mode (subtraction of the most often pixel, i.e. black space)
methods. Background-corrected images were then passed into basal body
segmentation, which segmented basal body using size and a simple
auto-threshold to convert the signal into a binary mask, which was further
refined using a user-defined assay optimized radius (∼50 pixels). Upper and
lower size filters were then applied to remove aggregates from the masked
image. Next, the protocol segmented primary cilia based on the acetylated
α-tubulin (acTub) channel. This was one of the trickier and elaborate parts of
the protocol because it involved identifying a small subpopulation of the total
acTub. Here, the acTub channel was first subjected to an aggressive linear
contrast enhancement applied to the selected field which set 1% of the
labeling intensity to saturation and 98% to the main. Although this resulted in
essentially a binary image, therewas still some noise associatewith the signal.
To resolve this issue a local background subtraction under the local basal body
mask was applied. This was performed by constructing a normalization mask
which was then multiplied by the original contrasted image. Once
normalized, the pixel intensities below the 80th percentile under the local
basal body masks were removed. A cluster-based segmentation was then
applied to the now normalized background subtracted image. This approach
helped identify objects and divide them into three intensity ranges: high,
medium and background. Medium intensity regions were removed, resulting
in only the high intensity regions being selected. It was important to use a
three-category approach here because sometimes the cilia presided over a
complex network of other signals, which would be picked up if using a binary
segmentation approach. A primary touching object filter was next applied to
ensure that only axonemes (a microtubule extension) touching the basal body
are considered as potential primary cilia. Statistical filtering involved a user-
defined size exclusion filter, and a ratio filter was applied to remove objects
that took up the entire mask, which was the case with mitotic-organizing
centers. A signal-to-background ratio was used for filtering, which used the
mean pixel intensity of the axoneme mask to the local background (this filter
used the original acTub image). The final filter used the condition that
candidate primary cilia must be outside of two standard deviations from the
mean pixel intensity under the local centrosome mask. Object labels that
contained both a basal body and cilia label were then assigned a Boolean
value of one; if the basal body alonewas defined, a Boolean value of zerowas
assigned. The mean of the Boolean value was taken to calculate the
percentage of ciliated cells.
Using the values from the segmentation protocols described above, a Z′
value was calculated using siC (scrambled control) DMSO-treated wells, as
a positive control, and siVHL treated with sulforaphane (sulphoraphane
causes loss of primary cilia; P.C. and R.D., unpublished data) as negative
controls. Using these we obtained a Z′ factor of ∼0.6, indicating that we had
developed a robust assay. To identify hits from the plates a Z-score was
calculated using the mean and standard deviation compared to the siVHL
DMSO-treated wells. Partially toxic wells were excluded on the criteria that
the cell density was lower than 80% of the mean cell count in the siC
DMSO-treated wells. Active wells were selected as wells that were not
filtered out by the toxicity filter and were outside of three standard
deviations of the value for siVHL DMSO-treated wells.
Immunocytochemistry
Immunofluorescence staining to observe primary cilia was performed as
published previously (Dere et al., 2015; Hasanov et al., 2017). Briefly,
hTERT RPE-1 cells or MEFs plated on glass coverslips (secondary
validation) were transfected, starved and treated for 48 h to induce cilia
formation (and in the case of MEFs were accompanied by 3 μM
4-hydroxytamoxifen; Sigma-Aldrich). Cells were fixed using 4%
paraformaldehyde (15 min), permeabilized with 0.5% Triton-X (10 min),
followed by blocking in 3.75% bovine serum albumin solution (1 h).
Primary antibodies for acetylated α-tubulin (clone 6-11B-1, 1:5000;
Sigma-Aldrich) and pericentrin (1:5000; Abcam, Cambridge, MA) were
applied in blocking buffer for 1 h. AlexaFluor 488 and 546 goat anti-mouse-
IgG or anti-rabbit-IgG secondary antibodies (Life Technologies) were
subsequently applied for another hour. Cells were counterstained using
DAPI (1:4000 of 1 mg/ml stock, Thermo Fisher Scientific, Waltham, MA)
and visualized using a Deltavision deconvolution microscope (Applied
Precision, Pittsburgh, PA) or a Nikon Ti2 inverted microscope (Nikon,
Melville, NY) at 60× magnification (secondary validation assays).
Immunoblotting
Whole-cell lysateswere collected in cold 1× cell lysis buffer (20 mMTris-HCl
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X-100,
2.5 mM sodium pyrophosphate) containing 1× complete protease inhibitor
(Roche, Mannheim, Germany), and 1 mM sodium orthovanadate (Na3VO4).
The following primary antibodies were used for immunoblotting:
anti-AURKA (cat. no. 4718S, 1:1000), anti-phospho-AURKA (cat. no.
3079S, 1:200), anti-NEDD9 (cat. no. 4044S, 1:1000) and anti-HDAC6 (cat.
no. 7612S, 1:1000) from Cell Signaling Technologies (Danvers, MA); anti-
tubulin (DM1A, 1:10,000) from Santa Cruz Biotechnology (Dallas, TX).
Horseradish peroxidase-conjugated goat anti-mouse-IgG and goat
anti-rabbit-IgG secondary antibodies were also purchased from Santa Cruz
Biotechnology. Immunoblots were visualized using Pierce ECL (Thermo
Fisher Scientific) substrate.
RT-PCR analysis
Reverse transcriptase-PCR analysis was performed as described previously
(Dere et al., 2015; Hasanov et al., 2017). Briefly, mRNAwas isolated from
Fig. 4. Bexarotene regulates AURKA expression in VHL-deficient cells.
(A) VHL-proficient (siC) and VHL-deficient (siVHL) cells were treated with the
indicated doses of bexarotene for 48 h and blotted for the antibodies as shown.
Dashed lines indicate where lanes have been spliced from the same
immunoblot for illustration purposes. (B) Densitometric quantitation showing
the ratio of AURKA to tubulin for each of the conditions indicated. Black bars,
siC; gray bars, siVHL. n.s., not statistically significant; *P-value as indicated.
(C,D) RT-PCR analysis showing AURKA (C), and VHL (D) mRNA expression
inVHL-proficient (siC, black bars) andVHL-deficient (siVHL, gray bars) cells in
response to the indicated doses of bexarotene (serum-free medium for 48 h).
(E–G) Representative images of 786-0 RCC VHL-null cells under the
conditions indicated showing acetylated α-tubulin (cilia marker) in red, and
pericentrin (basal body marker) in green. Nuclei were counterstained in blue.
Insets show magnified basal bodies and cilia (cells do not present primary
cilia). Scale bars: 5 µm. (H) Immunoblot analysis of lysates from 786-0 and
786-0 VHLL cells blotted for the indicated antibodies. (I) Lysates from 786-0
cells treated with vehicle or bexarotene (1.0 µM) immunoblotted for the
indicated antibodies.
9
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs219923. doi:10.1242/jcs.219923
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
cells transfected with siControl/siVHL, and cDNAwas prepared by reverse
transcription (Superscript III, Life Technologies). Gene expression was
assessed by real-time quantitative PCR using specific TaqMan probes
(Thermo Fisher Scientific, Waltham, MA), and a TaqMan Fast Universal
master mix on a Viia7 system (Thermo Fisher Scientific, Waltham, MA).
mRNA expression was evaluated for VHL, AURKA, GLI1, PTCH and
Fig. 5. Bexarotene decreases tumor incidence in a tumor xenograft model of RCC. (A) Schematic depicting the workflow outlining the treatment
regimen using bexarotene. (B) Rate of tumor take plotted as a percentage of lesions greater than 200 mm3 in size (tumor positive) at each of the indicated
time points [week (W)1–W8] for vehicle (circles) and bexarotene (squares)-treated groups. (C) Representative H&E stained images (10× objective) of xenograft
tumors from vehicle and bexarotene-treated animals. Scale bars: 500 µm. (D) Representative Ki67-stained images (10× objective) of xenograft tumors from
vehicle- and bexarotene-treated animals. Scale bars: 500 µm. (E) Final tumor volume (mm3) measured following euthanasia of the mice treated with vehicle
(circles) or bexarotene (squares). (F) Final tumor weight (g) measured for each tumor excised from mice treated with either vehicle (circles) or bexarotene
(squares) at the time of euthanasia as shown. (G) Lysates from tumors of vehicle- and bexarotene-treated xenografts immunoblotted for the indicated antibodies.
(H) Densitometric analysis showing a ratio of phospho-AURKA to total AURKA in vehicle- (circles) and bexarotene (squares)-treated xenograft tumors. * denotes
statistical significance between the groups as indicated.
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PPIA (endogenous control). The following set of conditions were used for
each real-time reaction: 95°C for 20 min followed by 40 cycles of 1 s at
95°C and 20 s at 60°C. The real-time PCR reactions were all performed in
triplicate and were quantified using the −ΔΔ cycle threshold (CT) method.
786-0 tumor xenograft mouse model
In order to establish a RCC tumor xenograft model, athymic,
immunodeficient mice (Foxn1nu, JAX Labs, Bar Harbor, ME, USA), at
5–6 weeks of age, were injected with 786-0 cells (3×106 cells/0.1 ml)
subcutaneously on the right thigh and scruff of each mouse. The mice were
randomly divided into two groups, the vehicle (corn oil) control group (n=5,
two sites on each mouse, 10 lesions) and the bexarotene treatment group
(n=11, two sites on each mouse, 22 lesions) and were gavaged orally with
bexarotene at a dose of 50 mg/kg body weight/day. Tumors were measured
once weekly using digital calipers two weeks after commencement of drug
treatment. Animals were killed 10 weeks following bexarotene treatment
and tumors were re-measured to get final tumor weights and volumes. For
tumor volume, the major and minor axes of the tumor were measured, and
volume calculated using the formula; length×width×width/2. Specifically,
for tumor take, only lesions greater than 200 mm3 were considered to be
bona fide tumors (tumor present). Tumor tissue harvested at the time of
killing was subsequently fixed in formalin and stained for H&E and Ki67
and imaged on a Nikon Ci-E microscope (Nikon, Melville, NY). All animal
studies were performed in compliance with Institutional IACUC approval.
Statistics
Densitometric analyses were performed using ImageQuant (GE Healthcare
Life Sciences, Pittsburgh, PA). Significance for the in vitro data (densitometry
and RT-PCR analyses) was determined by using Student’s t-tests (two-tailed,
assuming equal variance) from at least three biological replicates.
Comparisons between groups for the animal studies were performed using
Kilmogorov–Smirnov D or Mann–Whitney tests. The standard error of mean
(s.e.m.) was calculated, and reported P-values less than 0.05 were considered
to be significant. All statistics were performed using Prism 7 (GraphPad, La
Jolla, CA) and Excel (Microsoft, Redmond, WA) software.
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